The patented Eyerising Myopia Management Device’s Repeated Low-level Red-light (RLRL) therapy is designed to be child-friendly, convenient to use at home, and more effective at controlling childhood myopia. The device is non-invasive and has no risk of infection. It can be used without additional medications, eyedrops, or contact lenses, with no known significant side effects. This makes it suitable and easily tolerated by children as young as 3 and up to 16. The device has been proven in published clinical trials to be effective in the treatment of myopia, dramatically slowing its progression by up to 87.7%.
Therapy involves looking into the device device for a 3-minute treatment, 2 times per day, 5 days per week, with a minimum of 4 hours between sessions. The device is controlled via a simple touchscreen and monitors patient use. The system also sends reminders to the child’s guardians to maintain patient compliance and maximize treatment efficacy.
